Oxagen Ltd
Oxagen is focused on becoming a significant biopharmaceutical company, developing a pipeline of novel drugs to treat inflammatory diseases. The Company has created a portfolio of valuable drug targets centred on the highly attractive class of receptors, GPCRS. Through its heritage in human genetics, Oxagen has validated a number of GPCR targets, many of them novel, and selected the most promising as drug targets.
Oxagen was established in April 1997 and initially focused on identifying drug targets through genetics. Since 2003 the Company has focused on building a drug discovery and development capability and pipeline around GPCR targets. The Company is based in Milton Park, south of Oxford..